Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | MicrobiomeTrials← Back to trialsNCT06880770
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-04-24Est. Completion: 2029-03
Enrollment target: 288 participants Locations- Research Site, Los Angeles, California, United States
- Clinical Research Site 4, Santa Clarita, California, United States
- Research Site, New Haven, Connecticut, United States
- Clinical Research Site 6, Springfield, Illinois, United States
- Research Site, Indianapolis, Indiana, United States
- Research Site, Kansas City, Kansas, United States
- Research Site, Ann Arbor, Michigan, United States
- Research Site, St Louis, Missouri, United States
- Clinical Research Site 5, North Platte, Nebraska, United States
- Research Site, New York, New York, United States
- Clinical Research Site 3, Greensboro, North Carolina, United States
- Research Site, Wilmington, North Carolina, United States
- Clinical Research Site 7, Philadelphia, Pennsylvania, United States
- Research Site, Pittsburgh, Pennsylvania, United States
- Clinical Research Site 1, Mesquite, Texas, United States
- Clinical Research Site 2, San Antonio, Texas, United States
- Research Site, Seattle, Washington, United States
Other microbiome trials you might be interested in
CardiovascularMetabolic DiseaseDyslipidemiasLipid DisorderHypertriglyceridemiaHeterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (sHTG)Mixed HyperlipemiaHypercholesterolaemia
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years…
Hialeah, United StatesEst. completion Jun 2027
Research Site, Ramos Mejía, Buenos Aires, ArgentinaResearch Site, Córdoba, Córdoba Province, ArgentinaResearch Site, Córdoba, Córdoba Province, ArgentinaResearch Site, Rosario, Santa Fe Province, ArgentinaResearch Site, Ciudad Autonoma Buenos Aires, ArgentinaResearch Site, Graz, AustriaResearch Site, Linz, AustriaResearch Site, Vienna, AustriaResearch Site, Fortaleza, Ceará, BrazilResearch Site, Belo Horizonte, Minas Gerais, BrazilResearch Site, Belo Horizonte, Minas Gerais, BrazilResearch Site, Belo Horizonte, Minas Gerais, BrazilResearch Site, Curitiba, Paraná, BrazilResearch Site, Porto Alegre, Rio Grande do Sul, BrazilResearch Site, Porto Alegre, Rio Grande do Sul, BrazilResearch Site, Pôrto Alegre, Rio Grande do Sul, BrazilResearch Site, São Paulo, São Paulo, BrazilResearch Site, São Paulo, São Paulo, BrazilResearch Site, São Paulo, BrazilResearch Site, Burgas, BulgariaResearch Site, Pleven, BulgariaResearch Center, Plovdiv, BulgariaResearch Site, Plovdiv, BulgariaResearch Site, Rousse, BulgariaResearch Site, Sofia, BulgariaResearch Site, Sofia, BulgariaResearch Site, Stara Zagora, BulgariaResearch Site, Montreal, Quebec, CanadaResearch Center, Beijing, Beijing Municipality, ChinaResearch Site, Guangzhou, Guangdong, ChinaResearch Site, Guiyang, Guizhou, ChinaResearch Site, Harbin, Heilongjiang, ChinaResearch Site, Luoyang, Henan, ChinaResearch Site, Luoyang, Henan, ChinaResearch Site, Nanyang, Henan, ChinaResearch Site, Zhuzhou, Hunan, ChinaResearch Center, Baotou, Inner Mongolia, ChinaResearch Site, Chifeng, Inner Mongolia, ChinaResearch Center, Nanchang, Jiangxi, ChinaResearch Center, Shanghai, Shanghai Municipality, ChinaResearch Site, Chengdu, Sichuan, ChinaResearch Center, Hangzhou, Zhejiang, ChinaResearch Site, Hangzhou, Zhejiang, ChinaResearch Site, Wenzhou, Zhejiang, ChinaResearch Site, Beijing, ChinaResearch Site, Changsha, ChinaResearch Site, Chengdu, ChinaResearch Site, Ch’ang-ch’un, ChinaResearch Site, Nanjing, ChinaResearch Site, Barranquilla, ColombiaResearch Site, Bogotá, ColombiaResearch Site, Bogotá, ColombiaResearch Site, Cali, ColombiaResearch Site, Cali, ColombiaResearch Site, Floridablanca, ColombiaResearch Site, Puerto Colombia, ColombiaResearch Site, Budapest, HungaryResearch Site, Budapest, HungaryResearch Site, Pécs, HungaryResearch Site, Szeged, HungaryResearch Site, Ashkelon, IsraelResearch Site, Jerusalem, IsraelResearch Site, Petah Tikva, IsraelResearch Site, Ramat Gan, IsraelResearch Site, Amman, JordanResearch Center, Amman, JordanResearch Site, Amman, JordanResearch Center, Irbid, JordanResearch Center, Irbid, JordanResearch Site, Riga, LatviaResearch Site, Riga, LatviaResearch Site, Tukums, LatviaResearch Site, Kaunas, LithuaniaResearch Site, Kaunas, LithuaniaResearch Site, Guadalajara, Jalisco, MexicoResearch Site, Mexico City, Mexico City, MexicoResearch Site, Querétaro City, Querétaro, MexicoResearch Site, Durango, MexicoResearch Site, Muscat, OmanResearch Site, Riyadh, Saudi ArabiaResearch Site, Riyadh, Saudi ArabiaResearch Site, Riyadh, Saudi ArabiaResearch Center, Belgrade, SerbiaResearch Site, Belgrade, SerbiaResearch Site, Pančevo, SerbiaResearch Center, Zaječar, SerbiaResearch Site, Singapore, SingaporeResearch Site, Singapore, SingaporeResearch Site, Seongnam-si, Gyeonggi-do, South KoreaResearch Site, Jeonju, Jeollabuk-do, South KoreaResearch Site, Busan, South KoreaResearch Site, Sejong, South KoreaResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Center, Gothenburg, SwedenResearch Center, Stockholm, SwedenResearch Site, Abu Dhabi, United Arab EmiratesResearch Site, Abu Dhabi, United Arab EmiratesResearch Site, Al Ain City, United Arab EmiratesResearch Site, Torquay, Devon, United KingdomResearch Site, London, Greater London, United KingdomResearch Site, Dundee, Tayside Region, United KingdomPhase 2
Recruiting
Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyc…
Nanjing, ChinaEst. completion Jun 2027
Severe Hypertriglyceridemia
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipi…
Phoenix, United StatesEst. completion Mar 2027